Neoadjuvant Immunoradiotherapy in Head & Neck Cancer

Sponsor

Providence Health & Services (Other)

Overall Status

Active, not recruiting

CT.gov ID

NCT03247712

Collaborator

Providence Cancer Center, Earle A. Chiles Research Institute (Other)

Enrollment

Location

Arms

106.5

Anticipated Duration (Months)

0.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to test the safety of neoadjuvant immunoradiotherapy as a safe means of down-staging Head and Neck Squamous Cell Carcinoma (HNSCC) prior to surgical resection.

Condition or Disease	Intervention/Treatment	Phase
Head and Neck Cancer Head and Neck Squamous Cell Carcinoma	Drug: Nivolumab Procedure: Surgical Resection Radiation: Radiation (5 days) Radiation: Radiation (3 days)	Phase 1/Phase 2

Detailed Description

This clinical trial uses nivolumab and radiotherapy prior to definitive surgical resection of tumors in patients with Head and Neck Squamous Cell Carcinoma (OHNSCC) with the primary objective of determining the safety and feasibility of preoperative immunoradiotherapy. In addition, tumor tissue, microbiome samples, and peripheral blood will be obtained for exploratory immunologic end points including measurements of tumor infiltrating immune cell populations based on flow cytometry and immunohistochemistry as well as circulating immunological parameters. This is the first study to evaluate the safety and efficacy of neoadjuvant radiation + PD-1 blockade in patients with HNSCC.

Estimated duration of 20 weeks: neoadjuvant immunoradiotherapy +/- surgery, followed by 6 doses of nivolumab 480mg IV q4wks +/- risk-adapted adjuvant therapy, per standard of care.

Phase I safety lead-in study (n = 6) evaluating the safety of neoadjuvant immunoradiotherapy in HNSCC, followed by phase II efficacy study (n = 28, total) to assess rate of down-staging after neoadjuvant immunoradiotherapy using Simon's two-stage design (futility assessment at n = 12).

The phase 1 portion of this study will require 6 patients and is therefore expected to complete in 6 months. Although non-surgical patients are eligible to enroll, they will not be counted toward accrual for either the primary safety endpoint, (as by definition, unplanned delay of surgery cannot exist); nor the secondary efficacy endpoint, as potential for surgical staging is absent.

So long as 2 or fewer surgical delays are observed (primary safety endpoint), the phase 2 portion of study will proceed (secondary efficacy endpoint). Patients will be followed for disease free and overall survival at 5 years.

Eligible patients may be enrolled unless a rate of unplanned surgical delay attributed to immunoradiotherapy is found to exceed 33% after enrollment of the first 6 patients. We estimate 10 to 20 patients per year will be enrolled.

Study Design

Study Type:

Interventional

Actual Enrollment :

22 participants

Allocation:

Non-Randomized

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Neoadjuvant Immunoradiotherapy: Head & Neck Cancer (NIRT-HNC)

Actual Study Start Date :

Jan 15, 2018

Anticipated Primary Completion Date :

Dec 1, 2025

Anticipated Study Completion Date :

Dec 1, 2026

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Treatment Cohort 1 Nivolumab administration (3 doses) and radiation (5 days) therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).	Drug: Nivolumab Nivolumab 240mg IV q2wks or 480mg IV q4wks Other Names: Opdivo Procedure: Surgical Resection Surgical Resection of Tumor Radiation: Radiation (5 days) 8Gy x 5 (Mon-Fri) GTV+3mm
Experimental: Treatment Cohort 2 Nivolumab administration (3 doses) and radiation (3 days) therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).	Drug: Nivolumab Nivolumab 240mg IV q2wks or 480mg IV q4wks Other Names: Opdivo Procedure: Surgical Resection Surgical Resection of Tumor Radiation: Radiation (3 days) 8Gy x 3 (Monday, Wednesday, Friday) GTV+3mm
Experimental: Treatment Cohort 3 Radiation (3 days) therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).	Drug: Nivolumab Nivolumab 240mg IV q2wks or 480mg IV q4wks Other Names: Opdivo Procedure: Surgical Resection Surgical Resection of Tumor Radiation: Radiation (3 days) 8Gy x 3 (Monday, Wednesday, Friday) GTV+3mm
Experimental: Treatment Cohort 4 Nivolumab administration (3 doses) and radiation (3 days) therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).	Drug: Nivolumab Nivolumab 240mg IV q2wks or 480mg IV q4wks Other Names: Opdivo Procedure: Surgical Resection Surgical Resection of Tumor Radiation: Radiation (3 days) 8Gy x 3 (Monday, Wednesday, Friday) GTV+3mm

Outcome Measures

Primary Outcome Measures

Number of patients with an Unplanned Delay to Surgery [Safety and Tolerability of Neoadjuvant Treatment] [6 weeks]
Safety endpoint: Number of patients with an Unplanned Delay to Surgery defined as any change to scheduled surgery date considered to be at least possibly related to neoadjuvant treatment.

Secondary Outcome Measures

Number of patients with decrease in tumor size or number of lymph nodes involved [Efficacy of Neoadjuvant Treatment] [6 weeks]
Efficacy endpoint: Number of patients with decrease in tumor size of greater than 10% or decrease in the number of lymph nodes involved by 10% by week 6.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients with squamous cell carcinoma of the head and neck region, (including mucosal,cutaneous, or nodal) who are planned for surgical resection and in the opinion of the investigator are able to safely undergo neoadjuvant anti-PD-1 and radiation. In addition, the following are eligible (but will not contribute toward total accrual): non-surgical cases that are planned for palliative RT or that refuse or are unfit for definitive concurrent chemotherapy.
HPV status as determined by p16 immunostain
Cohort 3: HPV-positive patients only
Cohort 4: HPV-negative patients only
Age 18 years or above with ability to give informed consent, comply with the protocol, and sign a study-specific consent document. Patients with history of psychiatric illness must be judged by the investigator as able to understand the investigational nature and risks associated with the therapy.
Eastern Cooperative Oncology Group (ECOG) performance status deemed suitable by investigator for study requirements.
Laboratory values (most recent), must be within 6 weeks of week 0 on study:

WBC ≥ 2000/uL, ANC ≥ 1000/uL
Hgb > 8g/dL (patients may be transfused to reach this level)
Platelets > 50,000 cells/mm3
Creatinine ≤ 3 x ULN
AST/ALT ≤ 5 x ULN for subjects without liver metastasis; or ≤ 8 x ULN for subjects with liver metastasis, [per investigator brochure]
Total bilirubin ≤ 3 x ULN, (except subjects with Gilbert's Syndrome, who must have a total bilirubin less than 3.0 mg/dL)
Negative pregnancy test (bHCG urine or serum, women of childbearing potential only)

Women of child-bearing potential (WOCBP) must agree to follow adequate contraceptive practices to avoid pregnancy for the duration of treatment with nivolumab plus 5 half-lives of nivolumab (75 days) plus 30 days (duration of ovulatory cycle) for a total of 105 days post-treatment completion.
Males who are sexually active with WOCBP must agree to follow adequate contraceptive practices to avoid pregnancy for the duration of treatment with study drug (s) plus 5 half lives of the study drug (75 days) plus 90 days (duration of sperm turnover) for a total of 165 days post-treatment completion.

Exclusion Criteria:

Any clinical factors such as bleeding, active infection, or psychiatric factors that in the judgment of the investigator would preclude safe participation and compliance with study procedures.
HNSCC for which radiation is not indicated during normal treatment course.
Need for chronic maintenance with oral steroids ≥20mg daily prednisone equivalent; inhaled, topical or non-absorbed steroids are acceptable.
History of or current active autoimmune disease, [e.g. including but not limited to inflammatory bowel diseases [IBD], rheumatoid arthritis, autoimmune hepatitis, systemic sclerosis (scleroderma and variants), systemic lupus erythematosus, autoimmune vasculitis, autoimmune neuropathies (such as Guillain-Barre syndrome)], which in the judgment of the investigator poses an active and significant morbidity risk. Vitiligo and adequately controlled endocrine deficiencies such as hypothyroidism are not exclusionary. Patient and investigator may opt to accept risk of autoimmune disease flare, based on shared-decision making with consideration of risk/benefit.